ArticleThe Journal of cell biology1988
RGD-containing peptides inhibit the synthesis of myelin-like membrane by cultured oligodendrocytes.
Article in The Journal of cell biology, 1988. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 47 citations in OpenAlex.
- αGlia · 2021Article
- Myelin proteolipid protein forms a complex with integrins and may participate in integrin receptor signaling in oligodendrocytes.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2002Article
- Pituitary adenylyl cyclase-activating polypeptide stimulates DNA synthesis but delays maturation of oligodendrocyte progenitors.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2001Article
- Negative regulation of oligodendrocyte differentiation by galactosphingolipids.The Journal of neuroscience : the official journal of the Society for Neuroscience · 1999Article
- Time-dependent reversal of long-term potentiation by an integrin antagonist.The Journal of neuroscience : the official journal of the Society for Neuroscience · 1998Article
- Phosphodiesterase I, a novel adhesion molecule and/or cytokine involved in oligodendrocyte function.The Journal of neuroscience : the official journal of the Society for Neuroscience · 1997Article
- Tenascin-R is an intrinsic autocrine factor for oligodendrocyte differentiation and promotes cell adhesion by a sulfatide-mediated mechanism.The Journal of neuroscience : the official journal of the Society for Neuroscience · 1997Article
- Cell death prevention, mitogen-activated protein kinase stimulation, and increased sulfatide concentrations in Schwann cells and oligodendrocytes by prosaposin and prosaptides.Proceedings of the National Academy of Sciences of the United States of America · 1997Article
- A role in migration for the alpha V beta 1 integrin expressed on oligodendrocyte precursors.The Journal of neuroscience : the official journal of the Society for Neuroscience · 1996Article
- Expression of a beta 1-related integrin by oligodendroglia in primary culture: evidence for a functional role in myelination.The Journal of cell biology · 1994Article
- Granulocyte-macrophage colony-stimulating factor mimicry and receptor interactions.Immunologic research · 1994Article
- O2A progenitor cells transplanted into the neonatal rat brain develop into oligodendrocytes but not astrocytes.Proceedings of the National Academy of Sciences of the United States of America · 1993Article
- Spatiotemporal segregation of endothelial cell integrin and nonintegrin extracellular matrix-binding proteins during adhesion events.The Journal of cell biology · 1990Article
- Reversible inhibition of oligodendrocyte progenitor differentiation by a monoclonal antibody against surface galactolipids.Proceedings of the National Academy of Sciences of the United States of America · 1989Article
- Evidence that an RGD-dependent receptor mediates the binding of oligodendrocytes to a novel ligand in a glial-derived matrix.The Journal of cell biology · 1988Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
A synthetic peptide derived from the fibronectin cell-binding domain, GRGDSP, inhibits the adhesion of rat oligodendrocytes to a number of substrates. However, while GRGDSP inhibited the adhesion of cells in a short term adhesion assay, the presence of the peptide did not prevent cells from adhering and thriving in longer term culture. The morphological characteristics of individual cells cultured with 0.1 mg/ml GRGDSP were similar to untreated cultures; small rounded cell bodies radiating numerous fine processes. Peptide-treated cultures were inhibited in their ability to produce myelin specific components. The characteristic developmental peak in sulfolipid synthesis which occurs both in vivo and in vitro was completely inhibited when cells were cultured with GRGDSP. In addition, the synthesis of myelin basic protein was inhibited. Ultrastructurally, cells treated with GRGDSP showed a greatly reduced number of multilamellar myelin-like membrane figures than cells grown without peptide or those grown with GRADSP. Cultured oligodendrocytes did not become sensitive to inhibition of sulfolipid synthesis by GRGDSP until a period immediately preceding the peak in sulfolipid biosynthesis. The effects of pretreatment with peptide for 5 d before this time were completely reversible. Pretreatment which extended into the time of peak myelin synthesis resulted in permanent impairment in the cell's ability to synthesize sulfolipid. The oligodendrocyte's ability to synthesize a myelin-like membrane in culture is, in part, inherent since it occurs in the absence of neurons. The present results indicate that myelin membrane production is also subject to external control since it appears that occupancy of an RGD-dependent cell surface receptor during a critical period of in vitro development is required for the oligodendrocyte to produce myelin-like membrane.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.